No pain, no gain: A fallacy so far

Journal of Clinical Oncology

Volumn 33, Issue 3, 2015, Pages 235-237

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOCETAXEL; DOXORUBICIN; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; TUBULIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; EXEMESTANE; NITRILE; TRIAZOLE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG INDUCED DISEASE; EARLY CANCER; EDITORIAL; HIGH RISK PATIENT; HOT FLUSH; HUMAN; META ANALYSIS (TOPIC); MUSCULOSKELETAL DISEASE; PATIENT IDENTIFICATION; PERIPHERAL NEUROPATHY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME; VASOMOTOR DISORDER; ADRENERGIC SYSTEM; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; MUSCULOSKELETAL SYSTEM;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MUSCULOSKELETAL SYSTEM; NITRILES; TRIAZOLES; VASOMOTOR SYSTEM;

EID: 84921801553     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0919     Document Type: Editorial

References (14)

1. Stearns V, Chapman J-AW, Ma CX, et al: Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33:265-271, 2015
2. Liu HB, Wu Y, Lv T-F, et al: Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: A systematic review and meta-analysis. PLoS One 8:e55128, 2013
3. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011
4. Neugut AI, Hillyer GC, Kushi LH, et al: The Breast Cancer Quality of Care Study (BQUAL): A multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J 18:203-213, 2012
5. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
6. Mortimer JE, Flatt SW, Parker BA, et al: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421-426, 2008
7. Regan MM, Leyland-Jones B, Bouzyk M, et al: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst 104:441-451, 2012
8. Gradishar WJ, Anderson BO, Blair SL, et al: Breast cancer version 3.2014: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12:542-590, 2014
9. Moreno-Aspitia A, Patel T, Hillman D, et al: Paclitaxel-related peripheral neuropathy associated with improved outcome of patients with early stage HER2+ breast cancer who did not receive trastuzumab in the N9831 clinical trial. Cancer Res 69, 2009 (abstr 2100)
10. Schneider BP, Zhao F, Wang M, et al: Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 30:3051-3057, 2012
11. Chim K, Xie SX, Stricker CT, et al: Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 13:401, 2013
12. Cuzick J, Sestak I, Cella D, et al: Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 9:1143-1148, 2008
13. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
14. Fontein DB, Seynaeve C, Hadji P, et al: Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257-2264, 2013